All but over

There are times when we honestly wish when predictions we make don’t come true. Sadly that it is not the case when it comes to Senseonics who this morning issued a press release which stated;

“Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense® CGM System – today announced that its Board of Directors has decided to explore potential strategic alternatives to enhance stakeholder value. The Company is engaging Moelis & Company, LLC as its financial advisor and . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.